Tintelnot, Joseph http://orcid.org/0000-0003-4619-9433
Xu, Yang
Lesker, Till R.
Schönlein, Martin http://orcid.org/0000-0002-1010-0975
Konczalla, Leonie http://orcid.org/0000-0001-7674-1276
Giannou, Anastasios D.
Pelczar, Penelope
Kylies, Dominik
Puelles, Victor G. http://orcid.org/0000-0002-7735-5462
Bielecka, Agata A.
Peschka, Manuela
Cortesi, Filippo
Riecken, Kristoffer http://orcid.org/0000-0001-9050-6766
Jung, Maximilian
Amend, Lena http://orcid.org/0000-0002-5066-7140
Bröring, Tobias S.
Trajkovic-Arsic, Marija
Siveke, Jens T. http://orcid.org/0000-0002-8772-4778
Renné, Thomas
Zhang, Danmei http://orcid.org/0000-0001-6048-4711
Boeck, Stefan http://orcid.org/0000-0002-1922-2127
Strowig, Till http://orcid.org/0000-0003-0185-1459
Uzunoglu, Faik G.
Güngör, Cenap http://orcid.org/0000-0002-5173-9492
Stein, Alexander
Izbicki, Jakob R.
Bokemeyer, Carsten
Sinn, Marianne
Kimmelman, Alec C.
Huber, Samuel http://orcid.org/0000-0001-9325-8227
Gagliani, Nicola http://orcid.org/0000-0001-8514-1395
Article History
Received: 15 February 2022
Accepted: 12 January 2023
First Online: 22 February 2023
Competing interests
: D.Z. received travel support from AstraZeneca and AMGEN, honoraria from AstraZeneca and Roche. S.B. reports honoraria from AstraZeneca, BMS, Celgene, Incyte, Janssen Cilag, MSD and Servier for scientific presentations and paid consulting, as well as research support from Celgene. J.T.S. receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech, and Servier. His institution receives research funding from Abalos Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche/Genentech; he holds ownership and serves on the Board of Directors of Pharma15. C.B. reports personal fees from Sanofi Aventis, Merck KgA, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly Imclone, Bayer Healthcare, GSO Contract Research, AOK Rheinland-Hamburg and Novartis. M. Sinn received honoraria from AstraZeneca, Amgen, BMS, MSD, Incyte, Pierre Fabre, Pfizer Servier and Sanofi and support for clinical research (institutional) from Amgen, AstraZeneca, Bayer, BMS, Incyte, MSD, Pierre Fabre, Roche and Servier. N.G. reports financial support from Roche. All of these are outside the submitted work. A.C.K. has financial interests in Vescor Therapeutics, OncoRev and is an inventor on patents pertaining to KRAS-regulated metabolic pathways and redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, targeting alanine transport, and the autophagic control of iron metabolism. A.C.K. is on the scientific advisory board of Rafael/Cornerstone Pharmaceuticals and has been a consultant for Deciphera and Abbvie. The remaining authors declare no competing interests.